Search Login Register
pegvisomant
Summary
Description:
is a genetically engineered analogue of human growth hormone that functions as a growth hormone-receptor antagonist; used to treat Acromegaly;
Also Known As:
B-2036 PEG; B2036-PEG; Pfizer brand of pegvisomant; Somavert
Networked: 210
relevant articles (45 outcomes,
49 trials/studies)
for this Drug
Key Diseases for which pegvisomant is
Relevant
-
Acromegaly
:
36 outcomes 39 studies in 170 results
-
Neoplasms (Cancer)
:
2 outcomes 7 studies in 24 results
-
Pituitary Neoplasms (Pituitary Adenoma)
:
2 outcomes 2 studies in 15 results
-
Insulin Resistance
:
2 outcomes 1 study in 4 results
-
Adenoma (Adenomas)
:
1 outcome 2 studies in 6 results
Show All >>
Drugs Related to pegvisomant
-
Insulin-Like Growth Factor I (IGF-1)
-
Somatostatin (Somatotropin Release-Inhibiting Factor)
-
Octreotide (Sandostatin)
-
Insulin (Novolin)
-
pegvisomant
-
Somatotropin Receptors (Growth Hormone Receptor)
-
Glucose (Dextrose)
-
Dopamine Agonists (Dopamine Agonist)
-
cabergoline
-
Growth Hormone (Somatotropin)
Show All >>
Therapies Related to pegvisomant
-
Radiotherapy
-
Drug Therapy (Chemotherapy)
-
Injections
-
Heterologous Transplantation (Xenotransplantation)
-
Aftercare (After-Treatment)
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.